| Investor | Madison Avenue Partners, LP |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Madison Avenue Partners, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | 13G/A | MAGN / Magnera Corporation | 1,780,649 | 1,590,616 | ||||
| 2026-05-15 | 13G/A | INDV / Indivior Pharmaceuticals, Inc. | 6,280,502 | 4,315,162 | ||||
| 2026-04-20 | 13G | STAA / STAAR Surgical Company | 2,854,710 | |||||
| 2026-03-04 | 13G | AIV / Apartment Investment and Management Company | 12,347,991 | |||||
| 2026-02-17 | 13G/A | MAGN / Magnera Corporation | 2,832,281 | 1,780,649 | ||||
| 2026-02-17 | 13G/A | INDV / Indivior Pharmaceuticals, Inc. | 7,438,153 | 6,280,502 | ||||
| 2026-02-17 | 13G/A | KROS / Keros Therapeutics, Inc. | 2,614,402 | 823,707 | ||||
| 2026-01-29 | 13G | MDRX / Veradigm Inc. | 3,242,932 | 7,167,999 | ||||
| 2025-11-14 | 13G/A | MAGN / Magnera Corporation | 3,198,329 | 2,832,281 | ||||
| 2025-11-14 | 13G/A | CRGX / CARGO Therapeutics, Inc. | 4,193,626 | 0 | ||||
| 2025-11-14 | 13G/A | SAGE / Sage Therapeutics, Inc. | 6,077,065 | 0 | ||||
| 2025-08-14 | 13G/A | SAGE / Sage Therapeutics, Inc. | 4,920,763 | 6,077,065 | ||||
| 2025-08-14 | 13G/A | CRGX / CARGO Therapeutics, Inc. | 3,113,693 | 4,193,626 | ||||
| 2025-05-14 | 13G | KROS / Keros Therapeutics, Inc. | 2,614,402 | |||||
| 2025-04-30 | 13D | SLRN / Acelyrin, Inc. | 5,089,260 | |||||
| 2025-04-28 | 13G | CRGX / CARGO Therapeutics, Inc. | 3,113,693 | |||||
| 2025-04-01 | 13G | SAGE / Sage Therapeutics, Inc. | 4,920,763 | |||||
| 2025-03-18 | 13G | INDV / Indivior Pharmaceuticals, Inc. | 7,438,153 | |||||
| 2025-02-14 | 13G/A | OVID / Ovid Therapeutics Inc. | 3,648,509 | 2,852,352 | ||||
| 2025-02-14 | 13G/A | WLY / John Wiley & Sons, Inc. | 2,290,206 | 2,229,904 | ||||
| 2024-11-14 | 13G | MAGN / Magnera Corporation | 3,198,329 | |||||
| 2024-11-14 | 13G/A | MDRX / Veradigm Inc. | 6,100,902 | 3,242,932 | ||||
| 2024-11-14 | 13G/A | TBPH / Theravance Biopharma, Inc. | 8,511,350 | 9,511,150 | ||||
| 2024-11-14 | 13G/A | CEE / The Central and Eastern Europe Fund, Inc. | 371,267 | 79,400 | ||||
| 2024-09-30 | 13G | WLY / John Wiley & Sons, Inc. | 2,290,206 | |||||
| 2024-07-24 | 13G/A | ONL / Orion Properties Inc. | 2,989,565 | 150,449 | ||||
| 2024-06-10 | 13G | MDRX / Veradigm Inc. | 6,100,902 | |||||
| 2024-05-30 | 13G | GHC / Graham Holdings Company | 223,226 | |||||
| 2024-05-03 | 13G/A | TBPH / Theravance Biopharma, Inc. | 7,012,226 | 8,511,350 | ||||
| 2024-02-14 | 13G/A | OVID / Ovid Therapeutics Inc. | 3,609,054 | 3,648,509 | ||||
| 2024-02-14 | 13G/A | ONL / Orion Properties Inc. | 4,781,496 | 2,989,565 | ||||
| 2024-02-14 | 13G/A | GIII / G-III Apparel Group, Ltd. | 3,377,516 | 1,323,110 | ||||
| 2024-01-22 | 13G | CEE / The Central and Eastern Europe Fund, Inc. | 371,267 | |||||
| 2023-12-11 | 13G/A | LNSR / LENSAR, Inc. | 669,046 | 45,743 | ||||
| 2023-07-31 | 13G | OVID / Ovid Therapeutics Inc. | 3,609,054 | |||||
| 2023-02-23 | 13G | GIII / G-III Apparel Group, Ltd. | 3,377,516 | |||||
| 2023-02-14 | 13G/A | TBPH / Theravance Biopharma, Inc. | 6,648,025 | 7,012,226 | ||||
| 2023-02-14 | 13G/A | ONL / Orion Properties Inc. | 4,137,453 | 4,781,496 | ||||
| 2023-02-14 | 13G/A | PFSW / PFSWEB Inc | 2,394,072 | 2,633,189 | ||||
| 2023-02-14 | 13G/A | LNSR / LENSAR, Inc. | 676,109 | 669,046 | ||||
| 2022-04-14 | 13G | ONL / Orion Properties Inc. | 4,137,453 | |||||
| 2022-03-04 | 13G/A | PFSW / PFSWEB Inc | 1,635,961 | 2,394,072 | ||||
| 2022-02-14 | 13G/A | TBPH / Theravance Biopharma, Inc. | 4,567,413 | 6,648,025 | ||||
| 2022-02-14 | 13G/A | PFSW / PFSWEB Inc | 1,621,725 | 1,635,961 | ||||
| 2022-02-14 | 13G/A | LNSR / LENSAR, Inc. | 637,208 | 676,109 | ||||
| 2022-02-14 | 13G/A | SLVM / Sylvamo Corporation | 2,213,695 | 2,090,335 | ||||
| 2022-02-14 | 13G/A | JRVR / James River Group Holdings, Inc. | 2,300,490 | 794,837 | ||||
| 2021-11-05 | 13G | JRVR / James River Group Holdings, Inc. | 2,300,490 | |||||
| 2021-11-01 | 13G | SLVM / Sylvamo Corporation | 2,213,695 | |||||
| 2021-10-22 | 13G | PFSW / PFSWEB Inc | 1,621,725 | |||||
| 2021-09-27 | 13G | TBPH / Theravance Biopharma, Inc. | 4,567,413 | |||||
| 2021-05-27 | 13D/A | 85172J101 / Springleaf Holdings, Inc. | 1,767,193 | |||||
| 2021-03-12 | 13D | 85172J101 / Springleaf Holdings, Inc. | 2,289,999 | |||||
| 2021-03-12 | 13D | 85172J101 / Springleaf Holdings, Inc. | 2,289,999 | |||||
| 2021-02-16 | 13G | STGW / Stagwell Inc. | 3,871,434 | 3,871,434 | ||||
| 2021-02-16 | 13G | STGW / Stagwell Inc. | 3,871,434 | 3,871,434 | ||||
| 2021-02-12 | 13G | LNSR / LENSAR, Inc. | 637,208 | |||||
| 2020-02-14 | 13G | SPNV / Supernova Partners Acquisition Company Inc - Class A | 793,858 |
